Media-News

Be the most trusted biotech company

2022-08-26

The NDA for New Indication of Henlius Anti-PD-1 mAb Serplulimab in Combination with Chemotherapy for the First-line Treatment of Patients with Esophageal Squamous Cell Carcinoma Accepted by the NMPA
2022-08-18

Henlius 2022 H1 Results: Sharpen all-round edges, advance in evolution to Biopharma
2022-08-15

First Subject Dosed of the Phase 1 Clinical Trial of Serplulimab in Combination with Innovative Anti-LAG-3 mAb for the Treatment of Advanced/Metastatic Solid Tumours Patients
2022-07-29

Mars landing H - Boarding Call for Innovation
2022-07-25

Henlius HANQUYOU Received TGA Approval in Australia
2022-07-19

Henlius Denosumab Biosimilar HLX14 Received Clinical Trial Approval in Australia for the Phase 3 MRCT
2022-07-06

First Subject Dosed in China on Phase 1/2 Trial of Henlius' Anti-PD-L1×TIGIT Bispecific Antibody
2022-06-30

Henlius’ Novel Anti-TIGIT Fc Fusion Protein HLX53 IND Approved by NMPA
2022-06-28

Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies